{
    "clinical_study": {
        "@rank": "35413", 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the activity of multiple doses of oral rhIL-11 in\n      patients with active Crohn's disease (Crohn's Disease Activity Index [CDAI] score from\n      220-400)."
        }, 
        "brief_title": "Study Evaluating rhIL-11 in Active Crohn's Disease", 
        "completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Crohn Disease", 
            "Inflammatory Bowel Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Crohn Disease", 
                "Inflammatory Bowel Diseases", 
                "Intestinal Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented, signed  and dated informed consent to participate in this trial prior to\n             any study related procedures being performed.\n\n          -  Men and women age 16 years and over.\n\n          -  Diagnosis of Crohn's disease for at least 6 months that has been appropriately\n             documented and confirmed by radiological studies, endoscopy (with histological\n             examination preferred), or surgical pathology  (Patients with a diagnosis of Crohn's\n             disease for less than 6 months may be included if the diagnosis is confirmed by a\n             biopsy characteristic of Crohn's disease)\n\n        Exclusion Criteria:\n\n        Use of the following medications within the specified time period prior to randomization:\n\n          -  Nonsteroidal anti-inflammatory drugs (NSAIDs; including Cyclooxygenase-2 [COX-2]\n             inhibitors and >500 mg/day acetylsalicylic acid)\n\n          -  Codeine-containing compounds\n\n          -  Corticosteroid enemas"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "firstreceived_date": "June 27, 2002", 
        "id_info": {
            "nct_id": "NCT00040521", 
            "org_study_id": "3067K5-208", 
            "secondary_id": "B2491021"
        }, 
        "intervention": {
            "intervention_name": "Recombinant Human Interleukin-11 (rhIL-11)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Oprelvekin"
        }, 
        "keyword": [
            "Crohn's Disease", 
            "Active Crohns Disease"
        ], 
        "lastchanged_date": "February 7, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Arvada", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80002"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599-7032"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Orally Administered Recombinant Human Interleukin-11 (rhIL-11) for the Treatment of Patients With Active Crohn's Disease", 
        "overall_official": {
            "affiliation": "clinicaltrialinfo@wyeth.com", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2003", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040521"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2005"
    }, 
    "geocoordinates": {
        "null": "35.913 -79.056"
    }
}